NICE hurries to assess new hepatitis C drugs

The UK's cost-effectiveness watchdog is preparing to assess two new-and-highly-anticipated hepatitis C drugs--Merck's Victrelis and Vertex/Johnson & Johnson's Incivek--even before European regulators clear them for marketing. NICE says the drugs may meet an important medical need, and it wants to quickly move to evaluate them. Report